Dr. Esserman Discusses the I-SPY 2 Trial in Breast Cancer

Laura J. Esserman, MD, MBA
Published: Monday, Oct 08, 2018



Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the I-SPY 2 trial in breast cancer.

The I-SPY trials are neoadjuvant breast cancer trials designed for patients who are at a very high risk for early recurrence. Esserman explains that these trials aim to accelerate the pace of learning which agents are going to work for certain tumors. The I-SPY 2 trial (NCT01042379) is currently investigating neoadjuvant and personalized adaptive novel agents for the treatment of patients with breast cancer.

These trials are attempting to move the testing of new agents into the early-stage high-risk neoadjuvant setting. Esserman says that these trials test agents in the neoadjuvant setting, because that is where they can have the highest potential impact, or possibly cure patients.


Laura J. Esserman, MD, MBA, professor, University of California, San Francisco Helen Diller Comprehensive Cancer Center, 2018 Giant of Cancer Care® for Cancer Diagnostics, discusses the I-SPY 2 trial in breast cancer.

The I-SPY trials are neoadjuvant breast cancer trials designed for patients who are at a very high risk for early recurrence. Esserman explains that these trials aim to accelerate the pace of learning which agents are going to work for certain tumors. The I-SPY 2 trial (NCT01042379) is currently investigating neoadjuvant and personalized adaptive novel agents for the treatment of patients with breast cancer.

These trials are attempting to move the testing of new agents into the early-stage high-risk neoadjuvant setting. Esserman says that these trials test agents in the neoadjuvant setting, because that is where they can have the highest potential impact, or possibly cure patients.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x